LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

31.27 -0.03

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

31.26

Massimo

31.28

Metriche Chiave
By Trading Economics
Entrata	11M 64M
Vendite	-3.2M 149M
P/E Media del settore	18.075 50.102
EPS	0.79
Margine di Profitto	42.663
Dipendenti	182
EBITDA	2M 83M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+3.75% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	286M 3.8B
Apertura precedente	31.3
Chiusura precedente	31.27

Notizie sul Sentiment di mercato

By Acuity

40%

60%

306 / 344 Classifica in Healthcare

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 giu 2026, 20:30 UTC

Utili

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 giu 2026, 23:58 UTC

Discorsi di Mercato

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 giu 2026, 23:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 giu 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 giu 2026, 23:41 UTC

Discorsi di Mercato

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 giu 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 giu 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 giu 2026, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 giu 2026, 22:57 UTC

Discorsi di Mercato

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 giu 2026, 22:50 UTC

Discorsi di Mercato

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 giu 2026, 21:07 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 giu 2026, 21:07 UTC

Discorsi di Mercato

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 giu 2026, 21:00 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

2 giu 2026, 20:46 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:38 UTC

Utili

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 giu 2026, 20:21 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:12 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Product Rev $594M

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Loss $177M >PANW

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

3.75% in crescita

Previsioni per 12 mesi

Media 32.4 USD 3.75%

Alto 35 USD

Basso 31.5 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

306 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.